Document:

Exhibit 10.52

 

CONFIDENTIAL TREATMENT

 

SECOND
AMENDMENT TO THE

COMMERCIAL
SERVICES AGREEMENT

 

This Second Amendment to the
Commercial Services Agreement (this “Second Amendment”)
is made this 20th day of May, 2009 (the “Amendment
Effective Date”), by and between ASTRAZENECA PHARMACEUTICALS LP, a
Delaware limited partnership (“AstraZeneca”),
and CUBIST PHARMACEUTICALS, INC., a Delaware corporation (“Cubist”).

 

WHEREAS, AstraZeneca and
Cubist previously entered into that certain Commercial Services Agreement between
AstraZeneca and Cubist, dated as of July 1, 2008 (as amended as of February 26,
2009, the “Agreement”); and

 

WHEREAS, AstraZeneca and
Cubist desire to amend the Agreement to revise the Promotion Plan set forth in Exhibit M
of the Agreement.

 

NOW THEREFORE, in
consideration of the premises and the mutual covenants set forth herein and for
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereby agree as follows:

 

1.              Critical Care Target Accounts.  Exhibit M
to the Agreement is hereby amended so that as of the Amendment Effective Date,
the second sentence of Paragraph 1 of the Promotion Plan is hereby deleted and
replaced with the following: “[]*.  For purposes of
a Detail to []*, “Detail” shall mean a Representative of
the Sales Force meeting with []* or providing an in-service for []* at which []* is in attendance, such that
the relevant characteristics of the Product are described by the Representative
consistent with the requirements of this Agreement and Applicable Law and in a
manner that is customary in the industry for the purpose of promoting a
prescription pharmaceutical product.”

 

2.              Definitions.  All terms used, but not defined, in this
Second Amendment shall have the respective meanings set forth in the Agreement.

 

3.              Construction.  The principles set forth in Section 1.2
of the Agreement shall apply to this Second Amendment.

 

4.              Effective Date; Incorporation of Terms; Continuing Effect.  This Second Amendment shall be
deemed effective for all purposes as of the Amendment Effective Date.  The amendment set forth in this Second
Amendment shall be deemed to be incorporated in, and made a part of, the
Agreement, and the Agreement and this Second Amendment shall be read, taken and
construed as one and the same agreement (including with respect to the
provisions set forth in Article XVI (Miscellaneous) of the Agreement which
shall, as applicable, be deemed to apply to this Second Amendment (including
with respect to the governing law)).  Except as otherwise expressly amended by this
Second Amendment, the Agreement shall remain in full force and effect in
accordance with its terms and conditions.

 

5.              Counterparts.  This Second Amendment may be executed
simultaneously in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same
instrument.

 

*Confidential Treatment Requested. 
Omitted portions filed with the Securities and Exchange Commission (the
“Commission”).

 

 

IN WITNESS
WHEREOF, the parties, intending to be bound, have caused this Second Amendment
to be executed on their behalf by their duly authorized agent as of the day and
year first above written.

 

	
  ASTRAZENECA PHARMACEUTICALS LP

  	
   

  	
  CUBIST PHARMACEUTICALS, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:
  

  	
  /s/
  Marion McCourt

  	
   

  	
  By:

  	
  /s/
  Michael W. Bonney

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:
  

  	
  Marion
  McCourt

  	
   

  	
  Name:

  	
  Michael
  W. Bonney

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:
  

  	
  Vice
  President

  	
   

  	
  Title:
  

  	
  President
  and CEO

  

 

*Confidential Treatment
Requested.  Omitted portions filed with
the Commission.

 

2Exhibit
10.54

 

CONFIDENTIAL TREATMENT

 

THIRD AMENDMENT TO THE

COMMERCIAL SERVICES AGREEMENT

 

This Third Amendment to the Commercial Services
Agreement (this “Third Amendment”) is made this 30th day of September, 2009 (the “Amendment Effective Date”), by and between
ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership (“AstraZeneca”), and CUBIST PHARMACEUTICALS, INC., a Delaware
corporation (“Cubist”).

 

WHEREAS, AstraZeneca and Cubist previously entered
into that certain Commercial Services Agreement between AstraZeneca and Cubist,
dated as of July 1, 2008 (as amended as of February 26, 2009 and May 20,
2009, the “Agreement”); and

 

WHEREAS, AstraZeneca and Cubist desire to amend
certain provisions of the Agreement relating to the Promotion Plan and Annual
Baseline Sales, as set forth herein.

 

NOW THEREFORE, in consideration of the premises and
the mutual covenants set forth herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereby agree as follows:

 

1.                                      Promotion Plan. 
The Agreement is hereby amended so that Section 3.1(b) is
deleted in its entirety and replaced with the following:

 

“(b)         By October 16, 2009, for Calendar
Year 2010, and at least three (3) months prior to the commencement of each
Calendar Year thereafter, the parties shall update the Promotion Plan to
specify []* to be conducted by Cubist with respect to the Critical Care Target
Accounts and the Pediatric Target Accounts for such Calendar Year.  In addition to the foregoing annual updates,
the parties may modify the Promotion Plan from time to time by written
agreement.”

 

2.                                      Annual Baseline Sales. 
The Agreement is hereby amended so that Section 6.1(a) is
deleted in its entirety and replaced with the following:

 

“(a)         Subject to modification pursuant to Section 6.1(b),
the Annual Baseline Sales for Calendar Year 2008 and 2009 and the baseline
Gross Sales for each Calendar Quarter (“Quarterly
Baseline Sales”) in each such Calendar Year are set forth in Exhibit A.  For each Calendar Year thereafter, the []*.”

 

3.                                      Definitions. 
All terms used, but not defined, in this Third Amendment shall have the
respective meanings set forth in the Agreement.

 

4.                                      Construction. 
The principles set forth in Section 1.2 of the Agreement shall
apply to this Third Amendment.

 

*Confidential Treatment Requested. 
Omitted portions filed with the Securities and Exchange Commission (the
“Commission”).

 

1

 

5.                                      Effective Date;
Incorporation of Terms; Continuing Effect.  This Third
Amendment shall be deemed effective for all purposes as of the Amendment
Effective Date.  The amendment set forth
in this Third Amendment shall be deemed to be incorporated in, and made a part
of, the Agreement, and the Agreement and this Third Amendment shall be read,
taken and construed as one and the same agreement (including with respect to
the provisions set forth in Article XVI (Miscellaneous) of the Agreement
which shall, as applicable, be deemed to apply to this Third Amendment
(including with respect to the governing law)). 
Except as otherwise expressly amended by this Third Amendment, the
Agreement shall remain in full force and effect in accordance with its terms
and conditions.

 

6.                                      Counterparts. 
This Third Amendment may be executed simultaneously in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

 

[The remainder of this page has been
intentionally left blank.]

 

*Confidential Treatment Requested. 
Omitted portions filed with the Commission.

 

2

 

IN WITNESS WHEREOF, the parties, intending to be
bound, have caused this Third Amendment to be executed on their behalf by their
duly authorized agent as of the day and year first above written.

 

	
  ASTRAZENECA
  PHARMACEUTICALS LP

  	
   

  	
  CUBIST PHARMACEUTICALS, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:
  

  	
  /s/
  Marion E. McCourt

  	
   

  	
  By:

  	
  /s/
  David W. J. McGirr

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Marion
  E. McCourt

  	
   

  	
  Name:

  	
  David
  W. J. McGirr

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  VP,
  Cornerstone

  	
   

  	
  Title:

  	
  SVP,
  CFO

  

 

*Confidential Treatment Requested. 
Omitted portions filed with the Commission.

 

3Exhibit 10.55

 

CONFIDENTIAL TREATMENT

 

FOURTH AMENDMENT TO THE

COMMERCIAL SERVICES AGREEMENT

 

This Fourth Amendment to the Commercial Services
Agreement (this “Fourth Amendment”) is made this 15th day of October, 2009 (the “Amendment Effective Date”), by and between
ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership (“AstraZeneca”), and CUBIST PHARMACEUTICALS, INC., a Delaware
corporation (“Cubist”).

 

WHEREAS, AstraZeneca and Cubist previously entered
into that certain Commercial Services Agreement between AstraZeneca and Cubist,
dated as of July 1, 2008 (as amended as of February 26, 2009, May 20,
2009 and September 30,  2009,
the “Agreement”); and

 

WHEREAS, AstraZeneca and Cubist desire to amend
certain provisions of the Agreement relating to the Detailing of the Product to
Critical Care Target Accounts, as set forth herein.

 

NOW THEREFORE, in consideration of the premises and
the mutual covenants set forth herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereby agree as follows:

 

1.                                      Sales Force Obligations.  The Agreement is hereby amended so that the third
sentence of Section 3.1(a) is hereby deleted and replaced with the
following:

 

“Cubist shall
ensure that (A) each Detail by a Representative to []* is a Primary
Detail, and (B) each Detail by a Representative to []* is a Primary Detail
or a Secondary Detail.”

 

2.                                      Critical Care Target
Accounts.  The Agreement is hereby amended so that Section 1
of the Promotion Plan (Critical Care Target Accounts) set forth in Exhibit M
to the Agreement is hereby deleted in its entirety and replaced with the
following:

 

“1.           Critical Care Target
Accounts

 

[]*.  Notwithstanding anything contained in the
Agreement, for purposes of a Detail to []*, “Detail”
shall mean a Representative of the Sales Force meeting with []* or providing an
in-service for []* at which []* is in attendance, such that the relevant
characteristics of the Product are described by the Representative consistent
with the requirements of this Agreement and Applicable Law and in a manner that
is customary in the industry for the purpose of promoting a prescription
pharmaceutical product.”

 

3.                                      Exhibit J (Form of
Detail Report).  The Agreement is hereby amended so that Exhibit J
to the Agreement is hereby deleted and replaced with the Exhibit J
attached hereto as Attachment I.

 

*Confidential Treatment Requested.  Omitted portions filed with the Securities
and Exchange Commission (the “Commission”).

 

1

 

4.                                      Definitions. 
All terms used, but not defined, in this Fourth Amendment shall have the
respective meanings set forth in the Agreement.

 

5.                                      Construction. 
The principles set forth in Section 1.2 of the Agreement shall
apply to this Fourth Amendment.

 

6.                                      Effective Date;
Incorporation of Terms; Continuing Effect.  This Fourth
Amendment shall be deemed effective for all purposes as of the Amendment
Effective Date.  The amendments set forth
in this Fourth Amendment shall be deemed to be incorporated in, and made a part
of, the Agreement, and the Agreement and this Fourth Amendment shall be read,
taken and construed as one and the same agreement (including with respect to
the provisions set forth in Article XVI (Miscellaneous) of the Agreement
which shall, as applicable, be deemed to apply to this Fourth Amendment
(including with respect to the governing law)). 
Except as otherwise expressly amended by this Fourth Amendment, the
Agreement shall remain in full force and effect in accordance with its terms
and conditions.

 

7.                                      Counterparts. 
This Fourth Amendment may be executed simultaneously in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

 

[The remainder of this page has been
intentionally left blank.]

 

*Confidential
Treatment Requested.  Omitted portions
filed with the Commission.

 

2

 

IN WITNESS WHEREOF, the parties, intending to be
bound, have caused this Fourth Amendment to be executed on their behalf by
their duly authorized agent as of the Amendment Effective Date.

 

	
  ASTRAZENECA
  PHARMACEUTICALS LP

  	
   

  	
  CUBIST PHARMACEUTICALS, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Marion E. McCourt

  	
   

  	
  By:

  	
  /s/ Michael Bonney

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Marion E. McCourt

  	
   

  	
  Name:

  	
  Michael Bonney

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  Vice President,
  Cornerstone

  	
   

  	
  Title:

  	
  President and CEO

  

 

*Confidential
Treatment Requested.  Omitted portions
filed with the Commission.

 

3

 

ATTACHMENT I

 

EXHIBIT J

FORM OF DETAIL
REPORT

 

Monthly/Quarterly
Report

Reporting Period:                              to                                    

 

Prescriber
Level Reporting

 

	
  []*

  	
   

  	
  []*

  	
   

  	
  []*

  	
   

  	
  []*

  	
   

  	
  []*

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  []*

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  []*

  	
   

  	
  []*

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  []*

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  []*

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  []*

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  []*

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

[]*

 

*Confidential Treatment Requested. 
Omitted portions filed with the Commission.

 

J-1

 

Monthly/Quarterly
Report

Reporting Period:                              to                         

 

Account
Level Reporting

 

	
  []*

  	
   

  	
  []*

  	
   

  	
  []*

  	
   

  	
  []*

  	
   

  	
  []*

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  []*

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  []*

  	
   

  	
  []*

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  []*

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  []*

  	
   

  	
  []*

  	
   

  

 

[]*

 

Report Created:                  

 

*Confidential Treatment Requested.  Omitted portions filed with the Commission.

 

J-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]